These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24987183)

  • 1. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma.
    Sil A; Das NK
    Indian J Pharmacol; 2014; 46(3):334-6. PubMed ID: 24987183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
    Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
    Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
    Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
    Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
    Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
    Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 10. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
    Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
    Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Poprach A; Pavlik T; Melichar B; Puzanov I; Dusek L; Bortlicek Z; Vyzula R; Abrahamova J; Buchler T;
    Ann Oncol; 2012 Dec; 23(12):3137-3143. PubMed ID: 22700990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of sorafenib-related adverse events: a clinician's perspective.
    Brose MS; Frenette CT; Keefe SM; Stein SM
    Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M; Fujita T; Amoh Y; Mii S; Matsumoto K; Iwamura M
    Urol Int; 2013; 91(4):482-3. PubMed ID: 23969404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
    Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
    Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
    Ogawa C; Morita M; Omura A; Noda T; Kubo A; Matsunaka T; Tamaki H; Shibatoge M; Tsutsui A; Senoh T; Nagano T; Takaguchi K; Tani J; Morishita A; Yoneyama H; Masaki T; Moriya A; Ando M; Deguchi A; Kokudo Y; Minami Y; Ueshima K; Sakurai T; Nishida N; Kudo M
    Oncology; 2017; 93 Suppl 1():113-119. PubMed ID: 29258090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
    Kusari A; Borok J; Han AM; Valderrama AJ; Friedlander SF
    Pediatr Dermatol; 2018 Jul; 35(4):e206-e209. PubMed ID: 29766555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW
    Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.